Warner Alpízar-Alpízar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Warner Alpízar-Alpízar has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
Martin Illemann
The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark (WA-A, ODL, IJC, GH-H, MP, MI)
5 shared publicationsArne Skarstein
Department of Clinical Medicine, University of Bergen, Bergen, Norway (AS)
4 shared publicationsKjell Ovrebo
Department of Surgical Sciences, University of Bergen, Bergen, Norway (KO)
4 shared publications- Michael Ploug
The Finsen Laboratory, Rigshospitalet, DK-2200 Copenhagen, Denmark
4 shared publications Ole Didrik Laerum
The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark (WA-A, ODL, IJC, GH-H, MP, MI)
4 shared publicationsVanessa Ramírez-Mayorga
Cancer Epidemiology Program, Institute for Health Research (INISA), University of Costa Rica, 11501-2060 San José, Costa Rica
3 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 10 (9)
Beyond PD-L1/PD-1: expression of PVR/TIGIT and TNFRSF14/BTLA axes in response to Helicobacter pylori and in gastric cancer lesions
Gastric cancer (GC) has a high mortality rate worldwide, mainly due to late detection and lack of effective treatments. Immune checkpoint (ICs) inhibitors have revolutionized cancer treatment; however, a substantial percentage of patients with GC do not respond to this treatment, which may be related to aspects underlying the conformation of the immune microenvironment during tumor development and progression. In this study, we assessed the role of Helicobacter pylori, the most recognized GC risk factor, in the concomitant induction of PD-L1, B7-H3, PVR, TNFRSF14, Gal-3, and Gal-9 in vitro. We also analyzed the expression of selected IC ligand-receptor axes in human GC lesions. The mRNA relative expression of PD-L1, PVR, and TNFRSF14 was significantly upregulated in human cell lines challenged with the bacterium. This was CagPAI dependent and further enhanced by PBMCs. In GC lesions, mRNA levels in the PVR/TIGIT and TNFRSF14/BTLA axes were higher than in the PD-L1/PD-1 axis. When the protein levels of these ICs axes were determined by flow cytometry on the different cell subpopulations of the tumor microenvironment, Tregs emerged as the lymphoid subpopulation contributing the most to the expression of PD-1, TIGIT, and BTLA receptors; their ligands were mainly expressed by GC cells. Our results suggest that, in addition to the PD-L1/PD-1 axis, PVR/TIGIT and TNFRSF14/BTLA axes may play a role in establishing an immunosuppressive microenvironment during GC development and progression. This study also highlights the potential relevance of Tregs as active players in shaping and maintaining an immunosuppressive milieu in GC lesions, in part through expression of ICs.
- 22 September 2026
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 10 (9)
Open AccessBeyond PD-L1/PD-1: expression of PVR/TIGIT and TNFRSF14/BTLA axes in response to Helicobacter pylori and in gastric cancer lesions
Gastric cancer (GC) has a high mortality rate worldwide, mainly due to late detection and lack of effective treatments. Immune checkpoint (ICs) inhibitors have revolutionized cancer treatment; however, a substantial percentage of patients with GC do not respond to this treatment, which may be related to aspects underlying the conformation of the immune microenvironment during tumor development and progression. In this study, we assessed the role of Helicobacter pylori, the most recognized GC risk factor, in the concomitant induction of PD-L1, B7-H3, PVR, TNFRSF14, Gal-3, and Gal-9 in vitro. We also analyzed the expression of selected IC ligand-receptor axes in human GC lesions. The mRNA relative expression of PD-L1, PVR, and TNFRSF14 was significantly upregulated in human cell lines challenged with the bacterium. This was CagPAI dependent and further enhanced by PBMCs. In GC lesions, mRNA levels in the PVR/TIGIT and TNFRSF14/BTLA axes were higher than in the PD-L1/PD-1 axis. When the protein levels of these ICs axes were determined by flow cytometry on the different cell subpopulations of the tumor microenvironment, Tregs emerged as the lymphoid subpopulation contributing the most to the expression of PD-1, TIGIT, and BTLA receptors; their ligands were mainly expressed by GC cells. Our results suggest that, in addition to the PD-L1/PD-1 axis, PVR/TIGIT and TNFRSF14/BTLA axes may play a role in establishing an immunosuppressive microenvironment during GC development and progression. This study also highlights the potential relevance of Tregs as active players in shaping and maintaining an immunosuppressive milieu in GC lesions, in part through expression of ICs.
- Open Access
Prevalence of Colorectal Cancer Molecular Profiles Is Not Captured by a Single Age Threshold
Early- and average-onset colorectal cancer (CRC) are separated at age 50, but whether this defines a biological threshold remains unclear. To clarify this, we identified molecular profiles in nine harmonised cBioPortal CRC cohorts (4,609 patients) by fitting Bernoulli mixture models to 31 repair-state, genomic-burden and gene-alteration features, excluding age, sex and tumour site, and compared their prevalence using <50/≥50 and decade-resolved groups. Four profiles captured conventional/CIN-like (P1), intermediate MSS (P2), KRAS/PI3K/APC-rich (P3) and hypermutated/MSI-high (P4) states along a left-to-right anatomical gradient. Although molecular identities remained stable, profile prevalence followed non-linear P1/P4 and opposing linear P2/P3 age trajectories. Profile prevalence patterns did not follow age distance: profile composition at 30-39 differed from 50-59 but not clearly from 40-49 or 60-69. The age-50 threshold captured only 17.8% of decade-resolved deviance, whereas the optimal age-70 cut-off retained only 51.3%. Validation in 2,235 non-overlapping MSK-IMPACT patients (2,134 age-evaluable) reproduced molecular-feature patterns (r=0.96-1.00), age trajectories (r=0.90) and limited binary-threshold performance: age 50 and the optimal age-75 cut-off retained 6.2% and 49.4%, respectively. Thus, age reorganises the prevalence of shared CRC states rather than defining a biological threshold at age 50.
Open AccessPrevalence of Colorectal Cancer Molecular Profiles Is Not Captured by a Single Age Threshold
Early- and average-onset colorectal cancer (CRC) are separated at age 50, but whether this defines a biological threshold remains unclear. To clarify this, we identified molecular profiles in nine harmonised cBioPortal CRC cohorts (4,609 patients) by fitting Bernoulli mixture models to 31 repair-state, genomic-burden and gene-alteration features, excluding age, sex and tumour site, and compared their prevalence using <50/≥50 and decade-resolved groups. Four profiles captured conventional/CIN-like (P1), intermediate MSS (P2), KRAS/PI3K/APC-rich (P3) and hypermutated/MSI-high (P4) states along a left-to-right anatomical gradient. Although molecular identities remained stable, profile prevalence followed non-linear P1/P4 and opposing linear P2/P3 age trajectories. Profile prevalence patterns did not follow age distance: profile composition at 30-39 differed from 50-59 but not clearly from 40-49 or 60-69. The age-50 threshold captured only 17.8% of decade-resolved deviance, whereas the optimal age-70 cut-off retained only 51.3%. Validation in 2,235 non-overlapping MSK-IMPACT patients (2,134 age-evaluable) reproduced molecular-feature patterns (r=0.96-1.00), age trajectories (r=0.90) and limited binary-threshold performance: age 50 and the optimal age-75 cut-off retained 6.2% and 49.4%, respectively. Thus, age reorganises the prevalence of shared CRC states rather than defining a biological threshold at age 50.
- Open Access
- 6 August 2024
- Published by MDPI AG in Microorganisms
- Vol. 12 (8) , 1602
Protective Effects of Huo Xiang Zheng Qi Liquid on Clostridioides difficile Infection on C57BL/6 Mice
Background: Clostridioides difficile-associated disease (CDAD) is a major healthcare-associated infection. New treatment options for CDAD are needed. A traditional Chinese medicinal formula, Huo Xiang Zheng Qi (HXZQ), was chosen to test against CDAD in a mouse model. Methods: C57BL/6 mice were challenged with C difficile (ATCC 43255) orally; then received saline; vancomycin 25 mg/kg; or HXZQ in two different concentrations twice daily for 5 days. The animals’ body weight; clinical signs; and survival rates were registered daily. Fecal pellets from each animal were taken for PCR analysis as a control of infection. Results: 50% of the mice receiving saline died; 85.7% of the mice receiving vancomycin survived; 75% of the mice receiving HXZQ survived; and 87.5% of the mice receiving a 1:1 saline dilution of HXZQ survived. The HXZQ-treated groups were C. difficile PCR positive with loads less than that of the untreated mice. The weight loss in the vancomycin plus HXZQ 1:1 treated group; the vancomycin-treated group; and the untreated group were 3.08%, 4.06%, and 9.62%, respectively. Conclusions: our results showed that HXZQ can protect mice from CDAD-related death as effectively as vancomycin and the combination of vancomycin and HXZQ may give even better protection.
- 6 August 2024
- Published by MDPI AG in Microorganisms
- Vol. 12 (8) , 1602
Open AccessProtective Effects of Huo Xiang Zheng Qi Liquid on Clostridioides difficile Infection on C57BL/6 Mice
Background: Clostridioides difficile-associated disease (CDAD) is a major healthcare-associated infection. New treatment options for CDAD are needed. A traditional Chinese medicinal formula, Huo Xiang Zheng Qi (HXZQ), was chosen to test against CDAD in a mouse model. Methods: C57BL/6 mice were challenged with C difficile (ATCC 43255) orally; then received saline; vancomycin 25 mg/kg; or HXZQ in two different concentrations twice daily for 5 days. The animals’ body weight; clinical signs; and survival rates were registered daily. Fecal pellets from each animal were taken for PCR analysis as a control of infection. Results: 50% of the mice receiving saline died; 85.7% of the mice receiving vancomycin survived; 75% of the mice receiving HXZQ survived; and 87.5% of the mice receiving a 1:1 saline dilution of HXZQ survived. The HXZQ-treated groups were C. difficile PCR positive with loads less than that of the untreated mice. The weight loss in the vancomycin plus HXZQ 1:1 treated group; the vancomycin-treated group; and the untreated group were 3.08%, 4.06%, and 9.62%, respectively. Conclusions: our results showed that HXZQ can protect mice from CDAD-related death as effectively as vancomycin and the combination of vancomycin and HXZQ may give even better protection.
- Open Access
- 31 January 2022
- Published by Universidad Nacional de Costa Rica in Uniciencia
- Vol. 36 (1) , 1-9
Automated Quantification of Ki-67 on Gastric Epithelial Tissue based on Cell Nuclei Area Ratio
The objective was to develop an automated algorithm for the estimation of a protein (Ki-67) index based on cell nuclei area ratio of gastric epithelial tissue cells; for this purpose, digital histopathology images were used. An expert manually annotated each region of interest of the images. A proportion of Ki-67 positive and negative cells within that region was used to obtain the color distribution of the corresponding pixels. The histogram of each color distribution was modeled as a Gaussian and, later, thresholded for segmentation and classification. Finally, the Ki-67 index was estimated as the ratio between the segmented positive area of the nuclei divided by the total area of the positive and negative nuclei. The automated method has a strong correlation of 0.725 and a root mean square error of 0.293 when compared to the manual method, which gives certainty that the automated method can be used to analyze the proliferation rate. Furthermore, compared to manual classification, the presented method automatically classifies every image in the same Ki-67 category: low, intermediate, and high. Despite the small sample size, the utility of the presented method was demonstrated. However, the low number of scored images did not allow for thoroughly sampling the ranges of pixel values and intensities observed by pathologists, which will be addressed in future work.
- 31 January 2022
- Published by Universidad Nacional de Costa Rica in Uniciencia
- Vol. 36 (1) , 1-9
Open AccessAutomated Quantification of Ki-67 on Gastric Epithelial Tissue based on Cell Nuclei Area Ratio
The objective was to develop an automated algorithm for the estimation of a protein (Ki-67) index based on cell nuclei area ratio of gastric epithelial tissue cells; for this purpose, digital histopathology images were used. An expert manually annotated each region of interest of the images. A proportion of Ki-67 positive and negative cells within that region was used to obtain the color distribution of the corresponding pixels. The histogram of each color distribution was modeled as a Gaussian and, later, thresholded for segmentation and classification. Finally, the Ki-67 index was estimated as the ratio between the segmented positive area of the nuclei divided by the total area of the positive and negative nuclei. The automated method has a strong correlation of 0.725 and a root mean square error of 0.293 when compared to the manual method, which gives certainty that the automated method can be used to analyze the proliferation rate. Furthermore, compared to manual classification, the presented method automatically classifies every image in the same Ki-67 category: low, intermediate, and high. Despite the small sample size, the utility of the presented method was demonstrated. However, the low number of scored images did not allow for thoroughly sampling the ranges of pixel values and intensities observed by pathologists, which will be addressed in future work.
- 1 August 2021
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 362 (2) , 182-187
The TNF-A–857*T Polymorphism is Associated with Gastric Adenocarcinoma Risk in a Costa Rican Population
- 1 August 2021
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 362 (2) , 182-187
The TNF-A–857*T Polymorphism is Associated with Gastric Adenocarcinoma Risk in a Costa Rican Population
- Open Access
- 9 July 2020
- Published by MDPI AG in Microorganisms
- Vol. 8 (7) , 1019
Helicobacter pylori Colonization Drives Urokinase Receptor (uPAR) Expression in Murine Gastric Epithelium During Early Pathogenesis
(1) Background: Persistent Helicobacter pylori infection is the most important risk factor for gastric cancer. The urokinase receptor (uPAR) is upregulated in lesions harboring cancer invasion and inflammation. Circumstantial evidence tends to correlate H. pylori colonization with increased uPAR expression in the human gastric epithelium, but a direct causative link has not yet been established in vivo; (2) Methods: In a mouse model of H. pylori-induced gastritis, we investigated the temporal emergence of uPAR protein expression in the gastric mucosa in response to H. pylori (SS1 strain) infection; (3) Results: We observed intense uPAR immunoreactivity in foveolar epithelial cells of the gastric corpus due to de novo synthesis, compared to non-infected animals. This uPAR induction represents a very early response, but it increases progressively over time as do infiltrating immune cells. Eradication of H. pylori infection by antimicrobial therapy causes a regression of uPAR expression to its physiological baseline levels. Suppression of the inflammatory response by prostaglandin E2 treatment attenuates uPAR expression. Notwithstanding this relationship, H. pylori does induce uPAR expression in vitro in co-cultures with gastric cancer cell lines; (4) Conclusions: We showed that persistent H. pylori colonization is a necessary event for the emergence of a relatively high uPAR protein expression in murine gastric epithelial cells.
- 9 July 2020
- Published by MDPI AG in Microorganisms
- Vol. 8 (7) , 1019
Open AccessHelicobacter pylori Colonization Drives Urokinase Receptor (uPAR) Expression in Murine Gastric Epithelium During Early Pathogenesis
(1) Background: Persistent Helicobacter pylori infection is the most important risk factor for gastric cancer. The urokinase receptor (uPAR) is upregulated in lesions harboring cancer invasion and inflammation. Circumstantial evidence tends to correlate H. pylori colonization with increased uPAR expression in the human gastric epithelium, but a direct causative link has not yet been established in vivo; (2) Methods: In a mouse model of H. pylori-induced gastritis, we investigated the temporal emergence of uPAR protein expression in the gastric mucosa in response to H. pylori (SS1 strain) infection; (3) Results: We observed intense uPAR immunoreactivity in foveolar epithelial cells of the gastric corpus due to de novo synthesis, compared to non-infected animals. This uPAR induction represents a very early response, but it increases progressively over time as do infiltrating immune cells. Eradication of H. pylori infection by antimicrobial therapy causes a regression of uPAR expression to its physiological baseline levels. Suppression of the inflammatory response by prostaglandin E2 treatment attenuates uPAR expression. Notwithstanding this relationship, H. pylori does induce uPAR expression in vitro in co-cultures with gastric cancer cell lines; (4) Conclusions: We showed that persistent H. pylori colonization is a necessary event for the emergence of a relatively high uPAR protein expression in murine gastric epithelial cells.
- Open Access
- 24 September 2019
- Published by Wiley in Journal of Oncology
- Vol. 2019, 1-11
Gastric Cancer in the Era of Immune Checkpoint Blockade
Gastric cancer (GC) is one of the most important malignancies worldwide because of its high incidence and mortality. The very low survival rates are mainly related to late diagnosis and limited treatment options. GC is the final clinical outcome of a stepwise process that starts with a chronic and sustained inflammatory reaction mounted in response toHelicobacter pyloriinfection. The bacterium modulates innate and adaptive immunity presumably as part of the strategies to survive, which favors the creation of an immunosuppressive microenvironment that ultimately facilitates GC progression. T-cell exhaustion, which is characterized by elevated expression of immune checkpoint (IC) proteins, is one of the most salient manifestations of immunosuppressive microenvironments. It has been consistently demonstrated that the tumor-immune microenvironment(TIME)‐exhausted phenotype can be reverted by blocking ICs with monoclonal antibodies. Although these therapies are associated with long-lasting response rates, only a subset of patients derive clinical benefit, which varies according to tumor site. The search for biomarkers to predict the response to IC inhibition is a matter of intense investigation as this may contribute to maximize disease control, reduce side effects, and minimize cost. The approval of pembrolizumab for its use in GC has rocketed immuno-oncology research in this cancer type. In this review, we summarize the current knowledge centered around the immune contexture and recent findings in connection with IC inhibition in GC.
- 24 September 2019
- Published by Wiley in Journal of Oncology
- Vol. 2019, 1-11
Open AccessGastric Cancer in the Era of Immune Checkpoint Blockade
Gastric cancer (GC) is one of the most important malignancies worldwide because of its high incidence and mortality. The very low survival rates are mainly related to late diagnosis and limited treatment options. GC is the final clinical outcome of a stepwise process that starts with a chronic and sustained inflammatory reaction mounted in response toHelicobacter pyloriinfection. The bacterium modulates innate and adaptive immunity presumably as part of the strategies to survive, which favors the creation of an immunosuppressive microenvironment that ultimately facilitates GC progression. T-cell exhaustion, which is characterized by elevated expression of immune checkpoint (IC) proteins, is one of the most salient manifestations of immunosuppressive microenvironments. It has been consistently demonstrated that the tumor-immune microenvironment(TIME)‐exhausted phenotype can be reverted by blocking ICs with monoclonal antibodies. Although these therapies are associated with long-lasting response rates, only a subset of patients derive clinical benefit, which varies according to tumor site. The search for biomarkers to predict the response to IC inhibition is a matter of intense investigation as this may contribute to maximize disease control, reduce side effects, and minimize cost. The approval of pembrolizumab for its use in GC has rocketed immuno-oncology research in this cancer type. In this review, we summarize the current knowledge centered around the immune contexture and recent findings in connection with IC inhibition in GC.
- Open Access
- 19 September 2019
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 13, 962
Evaluation of the expression of the oncogen C-ERBB-2/HER2 in advanced gastric cancer cases from Costa Rica
Ecancermedicalscience is the peer-reviewed open access cancer journal founded by the European Institute of Oncology in Milan. We consider articles on all aspects of research relating to cancer, including molecular biology, genetics, pathophysiology, epide
- 19 September 2019
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 13, 962
Open AccessEvaluation of the expression of the oncogen C-ERBB-2/HER2 in advanced gastric cancer cases from Costa Rica
Ecancermedicalscience is the peer-reviewed open access cancer journal founded by the European Institute of Oncology in Milan. We consider articles on all aspects of research relating to cancer, including molecular biology, genetics, pathophysiology, epide
- 1 June 2019
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 10 (3) , 523-528
Evaluation of pharmacological therapies used in Costa Rica in patients with metastatic gastric cancer: a retrospective study
Background: Gastric cancer is one of the leading causes of cancer death worldwide. Surgery is regarded as the best curative treatment option for gastric cancer; however, a high proportion of cases are diagnosed at advanced stages, when tumors are unresectable. In the present study, we evaluated the impact of pharmacological therapies in the survival of 168 patients diagnosed with metastatic gastric cancer from Costa Rica, a country with very high incidence and mortality rates for this malignancy. Methods: We retrospectively reviewed 168 clinical records of patients diagnosed with metastatic gastric cancer from January 2009 to January 2012 at four major hospitals in Costa Rica. The Chi-square test or Fisher’s exact test was used for comparison of frequencies, while the ANOVA test was used for comparison of quantitative variables. OS and PFS analyses were performed using the Kaplan-Meier method. The Log-rank test was used to compare survival curves. Univariate and multivariate COX regression analyses were used to calculate the crude and adjusted hazard ratios (HR) with their 95% confidence interval (95% CI). Results: After a median follow-up of 46.5 months, the median survival difference between the two groups (pharmacological therapy vs. supportive care) was 5.6 months for PFS and 8.3 months for OS. Patients receiving triple therapy had 69% higher chance of progression than those receiving double therapy (HR =1.69, 95% CI: 1.04–2.73). The probability of dying is 88% higher for the patients receiving triple therapy than for those using double therapy (HR =1.88, 95% CI: 1.15–3.11). Conclusions: This study demonstrates that pharmacological therapies significantly increase the PFS and OS of those patients with metastatic gastric cancer in Costa Rica. The greatest benefit in terms of survival is observed with the use of duplets in comparison with the triplets in these patients.
- 1 June 2019
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 10 (3) , 523-528
Evaluation of pharmacological therapies used in Costa Rica in patients with metastatic gastric cancer: a retrospective study
Background: Gastric cancer is one of the leading causes of cancer death worldwide. Surgery is regarded as the best curative treatment option for gastric cancer; however, a high proportion of cases are diagnosed at advanced stages, when tumors are unresectable. In the present study, we evaluated the impact of pharmacological therapies in the survival of 168 patients diagnosed with metastatic gastric cancer from Costa Rica, a country with very high incidence and mortality rates for this malignancy. Methods: We retrospectively reviewed 168 clinical records of patients diagnosed with metastatic gastric cancer from January 2009 to January 2012 at four major hospitals in Costa Rica. The Chi-square test or Fisher’s exact test was used for comparison of frequencies, while the ANOVA test was used for comparison of quantitative variables. OS and PFS analyses were performed using the Kaplan-Meier method. The Log-rank test was used to compare survival curves. Univariate and multivariate COX regression analyses were used to calculate the crude and adjusted hazard ratios (HR) with their 95% confidence interval (95% CI). Results: After a median follow-up of 46.5 months, the median survival difference between the two groups (pharmacological therapy vs. supportive care) was 5.6 months for PFS and 8.3 months for OS. Patients receiving triple therapy had 69% higher chance of progression than those receiving double therapy (HR =1.69, 95% CI: 1.04–2.73). The probability of dying is 88% higher for the patients receiving triple therapy than for those using double therapy (HR =1.88, 95% CI: 1.15–3.11). Conclusions: This study demonstrates that pharmacological therapies significantly increase the PFS and OS of those patients with metastatic gastric cancer in Costa Rica. The greatest benefit in terms of survival is observed with the use of duplets in comparison with the triplets in these patients.